Promising Therapeutic Modalities for the Treatment of Alzheimer's Disease
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 229
Special Issue Editors
Interests: drug design; Alzheimer's disease; fragile x syndrome; autism
Special Issue Information
Dear Colleagues,
Alzheimer's disease is a leading cause of death among various CNS disorders. Reports have suggested the multifactorial nature of the disease. Thus, diverse therapeutic modalities have been explored for the treatment of diseases. Present Special Issues aim to publish research and review articles focused on small molecules, herbal drugs, biologics, and gene-editing technologies. Additionally, the review and research articles dealing with clustered regularly interspaced short palindromic repeats (CRISPR), targeted formulations and pathophysiology of the disease are also encouraged.
The Special Issue is seeking publications about established therapeutic modalities and recent interventions used to treat the disease.
Prof. Dr. Devendra Kumar
Dr. Ankit Ganeshpurkar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer's disease
- CNS active molecules
- herbal molecules
- biologics
- CRISPR
- CNS targeted formulations
- pathophysiology of Alzheimer's disease
